863 Mitten Road
Burlingame, CA 94010
650 900 4520
Full-time employees: 29
|Dr. Richard A. Miller M.D.||Co-Founder, Pres, CEO & Chairman||306k||N/A||1951|
|Dr. Peter A. Thompson FACP, M.D.||Co-Founder & Independent Director||47k||N/A||1960|
|Mr. Leiv Lea||Chief Financial Officer||388.73k||N/A||1954|
|Dr. William Benton Jones Ph.D.||Sr. VP of Pharmaceutical Devel.||346.42k||N/A||1966|
|Dr. James T. Rosenbaum M.D.||Sr. VP of Research||N/A||N/A||N/A|
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
Corvus Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.